2017
Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol
Wilson‐Robles H, Budke C, Miller T, Dervisis N, Novosad A, Wright Z, Thamm D, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T. Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. Veterinary And Comparative Oncology 2017, 15: 1564-1571. PMID: 28419683, DOI: 10.1111/vco.12302.Peer-Reviewed Original ResearchConceptsProgression-free survivalFree survivalMultivariable Cox regression modelsShorter progression-free survivalSurvival of dogsCox regression modelNon-Hodgkin lymphomaCHOP chemotherapyChemotherapy protocolsReferral institutionMedical recordsUnivariate analysisDoxorubicin dosesCanine lymphomaVeterinary oncologyDoxorubicin treatmentGeographical differencesLymphomaDogsSignificant differencesImmunophenotypeSurvivalRegression modelsGeographic differencesUS regionsRetrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia
Berger E, Johannes C, Post G, Rothchild G, Shiu K, Wetzel S, Fox L. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia. Journal Of Feline Medicine And Surgery 2017, 20: 95-102. PMID: 29172873, PMCID: PMC11129263, DOI: 10.1177/1098612x17695898.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCat DiseasesCatsFemaleIndolesMaleMast CellsNeoplasmsPyrrolesRetrospective StudiesTreatment OutcomeConceptsMast cell neoplasiaCell neoplasiaAdverse eventsClinical benefitUse of toceranibDuration of therapyPossible clinical benefitFurther prospective studiesMajority of catsVeterinary Internal MedicineHematologic eventsToceranib treatmentGastrointestinal involvementMedian doseMedian durationDose adjustmentTreatment breaksProspective studyConcurrent treatmentAmerican CollegeRetrospective evaluationAnatomic classificationFeline patientsGastrointestinal casesToceranib
2016
Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013
Olmsted G, Farrelly J, Post G, Smith J. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013. Journal Of Feline Medicine And Surgery 2016, 19: 568-575. PMID: 26951557, PMCID: PMC11128809, DOI: 10.1177/1098612x16638118.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaSquamous cell carcinomaToceranib phosphateCell carcinomaTreatment modalitiesFeline oral squamous cell carcinomaMetabolic toxicityNon-steroidal anti-inflammatory drugsCurrent treatment optionsFavorable toxicity profileCommon oral tumorAnti-inflammatory drugsMajority of catsAdditional therapyGastrointestinal toxicityGI toxicityMedian doseSurgical excisionTreatment delayPoor prognosisTreatment optionsOral tumorsDose reductionRadiation therapyToxicity profile
2015
Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone
Smith J, Kiupel M, Farrelly J, Cohen R, Olmsted G, Kirpensteijn J, Brocks B, Post G. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Veterinary And Comparative Oncology 2015, 15: 36-45. PMID: 25643820, DOI: 10.1111/vco.12140.Peer-Reviewed Original ResearchConceptsGrade II mast cell tumorsMast cell tumorsRecurrence rateLow proliferation activitySurgical excisionHistologic marginsKi67 indexCutaneous mast cell tumorsLow Ki67 indexLow AgNOR countsProliferation activityVariable biologic behaviorMedian followAncillary therapyDistant recurrenceLocal recurrenceClinical outcomesCell tumorsBiologic behaviorMast cellsAgNOR countsProliferation markersDogsRecurrenceTumors
2012
Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision
Dank G, Rassnick K, Sokolovsky Y, Garrett L, Post G, Kitchell B, Sellon R, Kleiter M, Northrup N, Segev G. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Veterinary And Comparative Oncology 2012, 12: 78-84. PMID: 22737988, DOI: 10.1111/j.1476-5829.2012.00338.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCarboplatinDog DiseasesDogsFemaleMaleMelanomaMouth NeoplasmsRetrospective StudiesTreatment OutcomeConceptsMalignant melanomaOverall median progression-free survivalMedian progression-free survivalProgression-free survival eventsAdjuvant carboplatin chemotherapyCommon oral malignancyMalignant oral melanomasMedian overall survivalProgression-free survivalOral malignant melanomaTreatment of dogsNumber of dosesCanine malignant melanomaCause of deathAdjuvant carboplatinCarboplatin chemotherapyMedian dosageOverall survivalSurgical resectionSystemic therapyLocal recurrenceOral malignanciesSurgical excisionRetrospective studyOral melanomaFeline exocrine pancreatic carcinoma: a retrospective study of 34 cases
Linderman M, Brodsky E, de Lorimier L, Clifford C, Post G. Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases. Veterinary And Comparative Oncology 2012, 11: 208-218. PMID: 22612638, DOI: 10.1111/j.1476-5829.2012.00320.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCarcinomaCat DiseasesCatsFemaleMalePancreatic NeoplasmsRetrospective StudiesConceptsMedian survivalRetrospective studySurvival timeNon-steroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyOverall median survivalPalpable abdominal massTime of diagnosisMedian survival timeExocrine pancreatic carcinomaHigh metastatic rateMetastatic diseaseAbdominal massClinical presentationMetastatic ratePoor prognosisPrognostic indicatorAggressive tumorsDrug therapyAbdominal effusionPancreatic cancerClinical signsPancreatic carcinomaPatientsWeight loss
2009
Asparaginase and MOPP Treatment of Dogs with Lymphoma
Brodsky E, Maudlin G, Lachowicz J, Post G. Asparaginase and MOPP Treatment of Dogs with Lymphoma. Journal Of Veterinary Internal Medicine 2009, 23: 578-584. PMID: 19645842, DOI: 10.1111/j.1939-1676.2009.0289.x.Peer-Reviewed Original ResearchConceptsOverall survival timeT-cell lymphomaT-cell phenotypeEntire study populationStudy populationSurvival timeMulticentric T-cell lymphomaMedian overall survival timeProgression-free survival timePresence of hypercalcemiaOverall response rateReferral veterinary hospitalAntigen receptor rearrangementMedian PFSMOPP chemotherapyMOPP treatmentPrevious chemotherapyLonger PFSChemotherapy protocolsMulticentric lymphomaRetrospective studyPolymerase chain reactionCytologic diagnosisReceptor rearrangementLymphoma